Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure

Kidney International

Volumn 79, Issue 4, 2011, Pages 432-442

  Komers, Radko ^a   Oyama, Terry T ^a   Beard, Douglas R ^b   Tikellis, Chris ^c   Xu, Bei ^a   Lotspeich, Daniel F ^a   Anderson, Sharon ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

connective tissue growth factor; diabetic nephropathy; fasudil; glomerulosclerosis; Rho associated kinases (ROCK); transforming growth factor

Indexed keywords

FASUDIL; INSULIN GLARGINE; LOSARTAN; MOLECULAR MARKER; RHO KINASE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; KIDNEY FIBROSIS; KIDNEY STRUCTURE; MALE; NEPHRECTOMY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; SCORING SYSTEM; STREPTOZOCIN DIABETES; TREATMENT DURATION;

EID: 79551507167     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.428     Document Type: Article

References (63)

1. Loirand G, Rolli-Derkinderen M, Pacaud P. RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 2005; 288: H1051-H1056.
2. Kanda T, Hayashi K, Wakino S et al. Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension 2005; 45: 724-729.
3. Kataoka C, Egashira K, Inoue S et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39: 245-250.
4. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201.
5. Kanda T, Wakino S, Hayashi K et al. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64: 2009-2019.
6. Kolavennu V, Zeng L, Peng H et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-723.
7. Peng F, Wu D, Gao B et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008; 57: 1683-1692.
8. Ishikawa Y, Nishikimi T, Akimoto K et al. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 2006; 47: 1075-1083.
9. Nishikimi T, Akimoto K, Wang X et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-1796.
10. Ozawa Y, Kobori H. Crucial role of Rho -nuclear factor kappa beta axis in angiotensin II-induced renal injury. Am J Physiol Renal Physiol 2007; 293: F100-F109.
11. Masumoto A, Mohri M, Shimokawa H et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105: 1545-1547.
12. Shimokawa H, Hiramori K, Iinuma H et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002; 40: 751-761.
13. Kawamura H, Yokote K, Asaumi S et al. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 276-281.
14. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005; 111: 3261-3268.
15. Miao L, Calvert JW, Tang J et al. Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats. Life Sci 2002; 71: 1175-1185.
16. Arita R, Hata Y, Nakao S et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009; 58: 215-226.
17. Gojo A, Utsunomiya K, Taniguchi K et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 568: 242-247.
18. Anderson S, Rennke H, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992; 41: 891-897.
19. Okada H, Danoff TM, Kalluri R et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997; 273: F563-F574.
20. Bonnet F, Cooper ME, Kawachi H et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874-877.
21. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239.
22. Ku CH, White KE, Dei Cas A et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57: 2824-2833.
23. Nishikimi T, Koshikawa S, Ishikawa Y et al. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 2007; 25: 1053-1063.
24. Kikuchi Y, Yamada M, Imakiire T et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192: 595-603.
25. Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 1990; 137: 1323-1332.
26. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
27. Teles F, Machado FG, Ventura BH et al. Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 2009; 75: 72-79.
28. Banes-Berceli AK, Shaw S, Ma G et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 2006; 291: F116-F121.
29. Nakamura A, Hayashi K, Ozawa Y et al. Vessel- and vasoconstrictor- dependent role of rho/rho-kinase in renal microvascular tone. J Vasc Res 2003; 40: 244-251.
30. Cavarape A, Bauer J, Bartoli E et al. Effects of angiotensin II, arginine vasopressin and tromboxane A2 in renal vascular bed: role of rho-kinase. Nephrol Dial Transplant 2003; 18: 1764-1769.
31. Savoia C, Tabet F, Yao G et al. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 2005; 23: 1037-1045.
32. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020.
33. Riser BL, Denichilo M, Cortes P et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38.
34. Hsieh TJ, Chen R, Zhang SL et al. Upregulation of osteopontin gene expression in diabetic rat proximal tubular cells revealed by microarray profiling. Kidney Int 2006; 69: 1005-1015.
35. Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55: 2993-3003.
36. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774.
37. Burns WC, Twigg SM, Forbes JM et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006; 17: 2484-2494.
38. Oldfield MD, Bach LA, Forbes JM et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853-1863.
39. Lee YJ, Han HJ. Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3{beta}, Snail1, and {beta}-catenin in renal proximal tubule cells. Am J Physiol Renal Physiol 2010; 298: F1263-F1275.
40. Noh H, Oh EY, Seo JY et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 2009; 297: F729-F739.
41. Patel S, Takagi KI, Suzuki J et al. RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation. J Am Soc Nephrol 2005; 16: 1977-1984.
42. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E et al. Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008; 25: 2447-2461.
43. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 2008; 74: 585-595.
44. Zhou L, Xue H, Yuan P et al. Angiotensin II type 1 receptor activation mediates high glucose-induced rat proximal tubule epithelial mesenchymal transition. Clin Exp Pharmacol Physiol 2010; 37: e152-e157.
45. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-1475.
46. Leroy P, Mostov KE. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol Biol Cell 2007; 18: 1943-1952.
47. Wang B, Herman-Edelstein M, Koh P et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-{beta}. Diabetes 2010; 59: 1794-1802.
48. Docherty NG, Calvo IF, Quinlan MR et al. Increased E-cadherin expression in the ligated kidney following unilateral ureteric obstruction. Kidney Int 2009; 75: 205-213.
49. Aaltonen P, Luimula P, Astrom E et al. Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001; 81: 1185-1190.
50. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239.
51. Shulman K, Rosen S, Tognazzi K et al. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7: 661-666.
52. Gealekman O, Brodsky SV, Zhang F et al. Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen. Kidney Int 2004; 66: 2337-2347.
53. Mott JD, Khalifah RG, Nagase H et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997; 52: 1302-1312.
54. Shankland SJ, Ly H, Thai K et al. Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res 1994; 75: 844-853.
55. Kasinath BS, Mariappan MM, Sataranatarajan K et al. mRNA translation: unexplored territory in renal science. J Am Soc Nephrol 2006; 17: 3281-3292.
56. Mariappan MM, Feliers D, Mummidi S et al. High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes 2007; 56: 476-485.
57. Sataranatarajan K, Mariappan MM, Lee MJ et al. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol 2007; 171: 1733-1742.
58. Lloberas N, Cruzado JM, Franquesa M et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404.
59. Qin J, Zhang Z, Liu J et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003; 64: 565-571.
60. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143.
61. Tikellis C, Thomas MC, Harcourt BE et al. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am J Physiol Endocrinol Metab 2008; 295: E323-E330.
62. Komers R, Schutzer WE, Reed JF et al. Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes 2006; 55: 1651-1659.
63. Komers R, Lindsley JN, Oyama TT et al. Renal p38 MAP kinase activity in experimental diabetes. Lab Invest 2007; 87: 548-558.